Comparing new drug SHR-A1811 to standard therapy for HER2+ breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new antibody-drug conjugate, SHR-A1811, against the combination of pyrotinib and capecitabine in people with HER2-positive advanced breast cancer that no longer responds to trastuzumab (Herceptin). Researchers want to see if SHR-A1811 works better than the standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your breast cancer is HER2-positive and has spread or cannot be removed by surgery.
- Your cancer has stopped responding to or progressed during trastuzumab treatment.
- You have at least one tumor that can be measured on scans.
- Your major organs (heart, liver, kidneys, blood) are working well enough.
- You have not had a previous antibody-drug conjugate that contains a topoisomerase I inhibitor (like DS-8201a).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether SHR-A1811 alone, or together with pyrotinib, given before surgery, can shrink HER2-positive breast cancer. It may help you respond better to treatment while making surgery easier.
This trial tests a new drug, SHR-1811, combined with carboplatin for advanced breast cancer that has HER2 expression (including low levels). It is for people who have already tried standard treatments and their cancer has spread or cannot be removed by surgery.
This study tests two ways to treat HER2-positive breast cancer before surgery: one uses a single drug (SHR-A1811), and the other uses that drug followed by a combination (THPy). The goal is to see which approach works better at shrinking tumors before surgery.
This study looks at whether giving a different antibody-drug conjugate (ADC) after a previous one can help people with advanced or metastatic breast cancer. It aims to find new options for patients who have already had ADC treatment.
This study tests a new drug, SHR-A1811, for women with HER2-positive breast cancer that has spread to the brain. The trial will see if the drug can shrink tumors in the brain and body.
This trial tests whether an artificial intelligence model can help doctors choose the best targeted therapy before surgery for HER2-positive breast cancer (a type of breast cancer with a protein called HER2). The goal is to improve how well the treatment works and reduce side effects.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.